CN116606861A - 编码vegf-a多肽的经修饰的rna、配制品和关于它们的用途 - Google Patents
编码vegf-a多肽的经修饰的rna、配制品和关于它们的用途 Download PDFInfo
- Publication number
- CN116606861A CN116606861A CN202310693718.2A CN202310693718A CN116606861A CN 116606861 A CN116606861 A CN 116606861A CN 202310693718 A CN202310693718 A CN 202310693718A CN 116606861 A CN116606861 A CN 116606861A
- Authority
- CN
- China
- Prior art keywords
- formulation
- vegf
- sub
- modified rna
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 560
- 238000009472 formulation Methods 0.000 title claims abstract description 329
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title abstract description 385
- 102000040650 (ribonucleotides)n+m Human genes 0.000 title abstract 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title description 164
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 title description 163
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 131
- 201000010099 disease Diseases 0.000 claims abstract description 118
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 64
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 62
- 229920001184 polypeptide Polymers 0.000 claims abstract description 46
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims description 310
- 239000000872 buffer Substances 0.000 claims description 308
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 272
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 256
- 239000011780 sodium chloride Substances 0.000 claims description 248
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 87
- 239000011575 calcium Substances 0.000 claims description 87
- 229910052791 calcium Inorganic materials 0.000 claims description 87
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 80
- 239000011777 magnesium Substances 0.000 claims description 80
- 229910052749 magnesium Inorganic materials 0.000 claims description 80
- 208000010125 myocardial infarction Diseases 0.000 claims description 74
- 150000002632 lipids Chemical class 0.000 claims description 66
- 230000001965 increasing effect Effects 0.000 claims description 65
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 60
- 102000004169 proteins and genes Human genes 0.000 claims description 58
- 229960000281 trometamol Drugs 0.000 claims description 56
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 52
- 239000002953 phosphate buffered saline Substances 0.000 claims description 52
- 150000001768 cations Chemical class 0.000 claims description 47
- 210000004027 cell Anatomy 0.000 claims description 46
- 239000002105 nanoparticle Substances 0.000 claims description 45
- 230000000747 cardiac effect Effects 0.000 claims description 41
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 33
- 230000002829 reductive effect Effects 0.000 claims description 31
- 238000001356 surgical procedure Methods 0.000 claims description 31
- 230000029663 wound healing Effects 0.000 claims description 30
- 230000001939 inductive effect Effects 0.000 claims description 29
- 206010019280 Heart failures Diseases 0.000 claims description 27
- 239000002904 solvent Substances 0.000 claims description 24
- 229920000642 polymer Polymers 0.000 claims description 23
- 210000000130 stem cell Anatomy 0.000 claims description 23
- 230000004064 dysfunction Effects 0.000 claims description 22
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 21
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 21
- 206010040943 Skin Ulcer Diseases 0.000 claims description 21
- 208000031225 myocardial ischemia Diseases 0.000 claims description 20
- 231100000019 skin ulcer Toxicity 0.000 claims description 20
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 19
- 239000002502 liposome Substances 0.000 claims description 19
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 18
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 claims description 17
- 206010034576 Peripheral ischaemia Diseases 0.000 claims description 17
- 230000033115 angiogenesis Effects 0.000 claims description 17
- 210000003748 coronary sinus Anatomy 0.000 claims description 17
- 239000003085 diluting agent Substances 0.000 claims description 17
- 239000003995 emulsifying agent Substances 0.000 claims description 17
- 208000014674 injury Diseases 0.000 claims description 17
- 108020004999 messenger RNA Proteins 0.000 claims description 17
- 230000008733 trauma Effects 0.000 claims description 17
- 239000004094 surface-active agent Substances 0.000 claims description 16
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 15
- 102000001974 Hyaluronidases Human genes 0.000 claims description 15
- 239000011258 core-shell material Substances 0.000 claims description 15
- 239000006185 dispersion Substances 0.000 claims description 15
- 239000002612 dispersion medium Substances 0.000 claims description 15
- 229960002773 hyaluronidase Drugs 0.000 claims description 15
- 239000003755 preservative agent Substances 0.000 claims description 15
- 239000002562 thickening agent Substances 0.000 claims description 15
- 206010029113 Neovascularisation Diseases 0.000 claims description 14
- 230000004217 heart function Effects 0.000 claims description 14
- 208000017169 kidney disease Diseases 0.000 claims description 14
- 230000035755 proliferation Effects 0.000 claims description 13
- 230000008929 regeneration Effects 0.000 claims description 12
- 238000011069 regeneration method Methods 0.000 claims description 12
- 238000007920 subcutaneous administration Methods 0.000 claims description 12
- 238000007918 intramuscular administration Methods 0.000 claims description 11
- 210000003240 portal vein Anatomy 0.000 claims description 11
- 230000004218 vascular function Effects 0.000 claims description 11
- 230000004663 cell proliferation Effects 0.000 claims description 10
- 230000010412 perfusion Effects 0.000 claims description 10
- 230000000250 revascularization Effects 0.000 claims description 10
- 231100000241 scar Toxicity 0.000 claims description 10
- 210000005167 vascular cell Anatomy 0.000 claims description 10
- 230000004936 stimulating effect Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 210000004165 myocardium Anatomy 0.000 claims description 7
- 230000003966 vascular damage Effects 0.000 claims description 5
- 108091026890 Coding region Proteins 0.000 claims description 2
- 230000020411 cell activation Effects 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 4
- 210000001519 tissue Anatomy 0.000 description 167
- 239000007924 injection Substances 0.000 description 141
- 238000002347 injection Methods 0.000 description 141
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 68
- 210000004962 mammalian cell Anatomy 0.000 description 61
- 210000002216 heart Anatomy 0.000 description 56
- 230000002861 ventricular Effects 0.000 description 52
- 239000003981 vehicle Substances 0.000 description 51
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 50
- 206010052428 Wound Diseases 0.000 description 50
- 229920002477 rna polymer Polymers 0.000 description 50
- 102000058223 human VEGFA Human genes 0.000 description 49
- 241000699670 Mus sp. Species 0.000 description 45
- 208000027418 Wounds and injury Diseases 0.000 description 44
- 230000000694 effects Effects 0.000 description 41
- 241000282414 Homo sapiens Species 0.000 description 38
- 206010061216 Infarction Diseases 0.000 description 38
- 230000007574 infarction Effects 0.000 description 33
- 241000700159 Rattus Species 0.000 description 29
- 241000282887 Suidae Species 0.000 description 28
- 239000003814 drug Substances 0.000 description 28
- 238000003384 imaging method Methods 0.000 description 26
- 239000008194 pharmaceutical composition Substances 0.000 description 26
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 24
- 239000007975 buffered saline Substances 0.000 description 24
- 150000007523 nucleic acids Chemical class 0.000 description 24
- 229910052760 oxygen Inorganic materials 0.000 description 24
- 239000001301 oxygen Substances 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 210000000038 chest Anatomy 0.000 description 23
- 210000003491 skin Anatomy 0.000 description 22
- 238000012360 testing method Methods 0.000 description 20
- 238000001890 transfection Methods 0.000 description 20
- 230000014616 translation Effects 0.000 description 20
- 230000006870 function Effects 0.000 description 19
- 239000007925 intracardiac injection Substances 0.000 description 19
- 239000002609 medium Substances 0.000 description 19
- 230000004048 modification Effects 0.000 description 19
- 238000012986 modification Methods 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 18
- 210000002889 endothelial cell Anatomy 0.000 description 18
- 230000000717 retained effect Effects 0.000 description 18
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 17
- 210000004351 coronary vessel Anatomy 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 244000309715 mini pig Species 0.000 description 15
- -1 suspending aids Substances 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 108060001084 Luciferase Proteins 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 210000005003 heart tissue Anatomy 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 14
- 230000008719 thickening Effects 0.000 description 14
- 231100000419 toxicity Toxicity 0.000 description 14
- 230000001988 toxicity Effects 0.000 description 14
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 13
- 102400001263 NT-proBNP Human genes 0.000 description 13
- 101800001904 NT-proBNP Proteins 0.000 description 13
- 208000024248 Vascular System injury Diseases 0.000 description 13
- 208000012339 Vascular injury Diseases 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 230000002107 myocardial effect Effects 0.000 description 13
- 238000010186 staining Methods 0.000 description 13
- 238000012384 transportation and delivery Methods 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 12
- 239000007951 isotonicity adjuster Substances 0.000 description 12
- 240000001307 Myosotis scorpioides Species 0.000 description 11
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 231100001231 less toxic Toxicity 0.000 description 11
- 238000002595 magnetic resonance imaging Methods 0.000 description 11
- 239000002121 nanofiber Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 239000002157 polynucleotide Substances 0.000 description 11
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 10
- 206010016654 Fibrosis Diseases 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 10
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 10
- 230000004761 fibrosis Effects 0.000 description 10
- 235000013928 guanylic acid Nutrition 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 230000035790 physiological processes and functions Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 102100026189 Beta-galactosidase Human genes 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 9
- 241000282898 Sus scrofa Species 0.000 description 9
- 239000003125 aqueous solvent Substances 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 108010005774 beta-Galactosidase Proteins 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 229960002725 isoflurane Drugs 0.000 description 9
- 230000029058 respiratory gaseous exchange Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000005089 Luciferase Substances 0.000 description 8
- 230000002491 angiogenic effect Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003636 conditioned culture medium Substances 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 238000002592 echocardiography Methods 0.000 description 8
- 230000002526 effect on cardiovascular system Effects 0.000 description 8
- 210000005240 left ventricle Anatomy 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 7
- 206010011086 Coronary artery occlusion Diseases 0.000 description 7
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 7
- 206010072170 Skin wound Diseases 0.000 description 7
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 7
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000010432 diamond Substances 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 230000004865 vascular response Effects 0.000 description 7
- SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 description 6
- AOKQNZVJJXPUQA-KQYNXXCUSA-M 7-methylguanosine 5'-phosphate(1-) Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O AOKQNZVJJXPUQA-KQYNXXCUSA-M 0.000 description 6
- 208000001778 Coronary Occlusion Diseases 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 230000006835 compression Effects 0.000 description 6
- FPUGCISOLXNPPC-IOSLPCCCSA-N cordysinin B Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 FPUGCISOLXNPPC-IOSLPCCCSA-N 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000002565 electrocardiography Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000006213 oxygenation reaction Methods 0.000 description 6
- 230000036316 preload Effects 0.000 description 6
- 230000000153 supplemental effect Effects 0.000 description 6
- 210000000115 thoracic cavity Anatomy 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 208000019553 vascular disease Diseases 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 5
- 108091036407 Polyadenylation Proteins 0.000 description 5
- 108091036066 Three prime untranslated region Proteins 0.000 description 5
- 102000013394 Troponin I Human genes 0.000 description 5
- 108010065729 Troponin I Proteins 0.000 description 5
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 5
- 230000029918 bioluminescence Effects 0.000 description 5
- 238000005415 bioluminescence Methods 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 5
- 238000002586 coronary angiography Methods 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 238000003306 harvesting Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 235000020925 non fasting Nutrition 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 238000002627 tracheal intubation Methods 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 210000002565 arteriole Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229920006227 ethylene-grafted-maleic anhydride Polymers 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000000004 hemodynamic effect Effects 0.000 description 4
- 230000007954 hypoxia Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000015788 innate immune response Effects 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 125000003835 nucleoside group Chemical group 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000002047 solid lipid nanoparticle Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- GRYSXUXXBDSYRT-WOUKDFQISA-N (2r,3r,4r,5r)-2-(hydroxymethyl)-4-methoxy-5-[6-(methylamino)purin-9-yl]oxolan-3-ol Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OC GRYSXUXXBDSYRT-WOUKDFQISA-N 0.000 description 3
- OTFGHFBGGZEXEU-PEBGCTIMSA-N 1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-3-methylpyrimidine-2,4-dione Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N(C)C(=O)C=C1 OTFGHFBGGZEXEU-PEBGCTIMSA-N 0.000 description 3
- QPHRQMAYYMYWFW-FJGDRVTGSA-N 1-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 QPHRQMAYYMYWFW-FJGDRVTGSA-N 0.000 description 3
- FPUGCISOLXNPPC-UHFFFAOYSA-N 2'-O-Methyladenosine Natural products COC1C(O)C(CO)OC1N1C2=NC=NC(N)=C2N=C1 FPUGCISOLXNPPC-UHFFFAOYSA-N 0.000 description 3
- RFCQJGFZUQFYRF-UHFFFAOYSA-N 2'-O-Methylcytidine Natural products COC1C(O)C(CO)OC1N1C(=O)N=C(N)C=C1 RFCQJGFZUQFYRF-UHFFFAOYSA-N 0.000 description 3
- OVYNGSFVYRPRCG-UHFFFAOYSA-N 2'-O-Methylguanosine Natural products COC1C(O)C(CO)OC1N1C(NC(N)=NC2=O)=C2N=C1 OVYNGSFVYRPRCG-UHFFFAOYSA-N 0.000 description 3
- RFCQJGFZUQFYRF-ZOQUXTDFSA-N 2'-O-methylcytidine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 RFCQJGFZUQFYRF-ZOQUXTDFSA-N 0.000 description 3
- OVYNGSFVYRPRCG-KQYNXXCUSA-N 2'-O-methylguanosine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=C(N)NC2=O)=C2N=C1 OVYNGSFVYRPRCG-KQYNXXCUSA-N 0.000 description 3
- SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 description 3
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 3
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 description 3
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 3
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 3
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 3
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 3
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- ZBYRSRLCXTUFLJ-IOSLPCCCSA-O N(2),N(7)-dimethylguanosine Chemical compound CNC=1NC(C=2[N+](=CN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C=2N=1)C)=O ZBYRSRLCXTUFLJ-IOSLPCCCSA-O 0.000 description 3
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229930185560 Pseudouridine Natural products 0.000 description 3
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 3
- 108091030071 RNAI Proteins 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
- 101150084041 WT1 gene Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 3
- 229960001736 buprenorphine Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 3
- 231100000294 dose-dependent toxicity Toxicity 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003978 infusion fluid Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 229960003299 ketamine Drugs 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000005246 left atrium Anatomy 0.000 description 3
- 238000001690 micro-dialysis Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 3
- 210000005245 right atrium Anatomy 0.000 description 3
- 210000005241 right ventricle Anatomy 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- NJQONZSFUKNYOY-JXOAFFINSA-N 5-methylcytidine 5'-monophosphate Chemical group O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 NJQONZSFUKNYOY-JXOAFFINSA-N 0.000 description 2
- 125000003345 AMP group Chemical group 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010051792 Infusion related reaction Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 230000026279 RNA modification Effects 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 2
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000012382 advanced drug delivery Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000027746 artery morphogenesis Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 210000001174 endocardium Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 210000002064 heart cell Anatomy 0.000 description 2
- 230000005986 heart dysfunction Effects 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003434 inspiratory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003601 intercostal effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
- 229960003793 midazolam Drugs 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 229960004134 propofol Drugs 0.000 description 2
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 239000006200 vaporizer Substances 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- 238000011265 2D-echocardiography Methods 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241001646765 Apini Species 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 108091027757 Deoxyribozyme Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229930184510 Mallotus Natural products 0.000 description 1
- 241001060384 Mallotus <angiosperm> Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 239000011542 SDS running buffer Substances 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000026448 Wilms tumor 1 Diseases 0.000 description 1
- 102100022748 Wilms tumor protein Human genes 0.000 description 1
- 101710127857 Wilms tumor protein Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000000848 adenin-9-yl group Chemical group [H]N([H])C1=C2N=C([H])N(*)C2=NC([H])=N1 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 125000004429 atom Chemical class 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229960001889 buprenorphine hydrochloride Drugs 0.000 description 1
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- MPBRYMWMMKKRGC-UHFFFAOYSA-M carbocyanin DBTC Chemical compound [Br-].C1=CC=CC2=C([N+](=C(C=C(C)C=C3N(C4=C5C=CC=CC5=CC=C4S3)CC)S3)CC)C3=CC=C21 MPBRYMWMMKKRGC-UHFFFAOYSA-M 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000001054 cardiac fibroblast Anatomy 0.000 description 1
- 238000013184 cardiac magnetic resonance imaging Methods 0.000 description 1
- 230000037198 cardiovascular physiology Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- HZHFFEYYPYZMNU-UHFFFAOYSA-K gadodiamide Chemical compound [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC HZHFFEYYPYZMNU-UHFFFAOYSA-K 0.000 description 1
- 229960005063 gadodiamide Drugs 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 208000010729 leg swelling Diseases 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000002479 lipoplex Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005244 lower chamber Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000010060 microvascular dysfunction Effects 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000008065 myocardial cell damage Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- SQMWSBKSHWARHU-SDBHATRESA-N n6-cyclopentyladenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 SQMWSBKSHWARHU-SDBHATRESA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- AIDBEARHLBRLMO-UHFFFAOYSA-M sodium;dodecyl sulfate;2-morpholin-4-ylethanesulfonic acid Chemical compound [Na+].OS(=O)(=O)CCN1CCOCC1.CCCCCCCCCCCCOS([O-])(=O)=O AIDBEARHLBRLMO-UHFFFAOYSA-M 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346979P | 2016-06-07 | 2016-06-07 | |
| US62/346979 | 2016-06-07 | ||
| US201662411091P | 2016-10-21 | 2016-10-21 | |
| US62/411091 | 2016-10-21 | ||
| US201662432005P | 2016-12-09 | 2016-12-09 | |
| US62/432005 | 2016-12-09 | ||
| PCT/US2017/036188 WO2017214175A1 (en) | 2016-06-07 | 2017-06-06 | Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto |
| CN201780048447.8A CN109790207B (zh) | 2016-06-07 | 2017-06-06 | 编码vegf-a多肽的经修饰的rna、配制品和关于它们的用途 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780048447.8A Division CN109790207B (zh) | 2016-06-07 | 2017-06-06 | 编码vegf-a多肽的经修饰的rna、配制品和关于它们的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116606861A true CN116606861A (zh) | 2023-08-18 |
Family
ID=59270113
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310693718.2A Pending CN116606861A (zh) | 2016-06-07 | 2017-06-06 | 编码vegf-a多肽的经修饰的rna、配制品和关于它们的用途 |
| CN201780048447.8A Active CN109790207B (zh) | 2016-06-07 | 2017-06-06 | 编码vegf-a多肽的经修饰的rna、配制品和关于它们的用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780048447.8A Active CN109790207B (zh) | 2016-06-07 | 2017-06-06 | 编码vegf-a多肽的经修饰的rna、配制品和关于它们的用途 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11866475B2 (enExample) |
| EP (2) | EP3464338B1 (enExample) |
| JP (3) | JP6859369B2 (enExample) |
| KR (4) | KR102376245B1 (enExample) |
| CN (2) | CN116606861A (enExample) |
| AU (2) | AU2017277277B2 (enExample) |
| CA (1) | CA3026500A1 (enExample) |
| CY (1) | CY1124667T1 (enExample) |
| DK (1) | DK3464338T3 (enExample) |
| ES (1) | ES2895421T3 (enExample) |
| HR (1) | HRP20211569T1 (enExample) |
| HU (1) | HUE056055T2 (enExample) |
| IL (1) | IL263370A (enExample) |
| LT (1) | LT3464338T (enExample) |
| MA (1) | MA45172B1 (enExample) |
| MX (1) | MX2018015110A (enExample) |
| PL (1) | PL3464338T3 (enExample) |
| PT (1) | PT3464338T (enExample) |
| RS (1) | RS62556B1 (enExample) |
| RU (1) | RU2756313C2 (enExample) |
| SG (2) | SG10202012175YA (enExample) |
| SI (1) | SI3464338T1 (enExample) |
| SM (1) | SMT202100586T1 (enExample) |
| TW (2) | TWI752036B (enExample) |
| WO (1) | WO2017214175A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116606861A (zh) | 2016-06-07 | 2023-08-18 | 摩登纳特斯有限公司 | 编码vegf-a多肽的经修饰的rna、配制品和关于它们的用途 |
| US11628227B2 (en) * | 2017-07-05 | 2023-04-18 | Wisconsin Alumni Research Foundation | Mineral coated microparticles for gene delivery in chronic wound therapy |
| WO2019089818A1 (en) | 2017-10-31 | 2019-05-09 | Modernatx, Inc. | Lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide |
| CN114173826A (zh) * | 2019-05-08 | 2022-03-11 | 阿斯利康(瑞典)有限公司 | 使用脂质纳米颗粒用于递送编码vegf-a多肽的经修饰的rna的方法和包含其的药物组合物 |
| JP7345888B2 (ja) * | 2021-06-17 | 2023-09-19 | 株式会社ニューギン | 遊技機 |
| WO2023061985A2 (en) * | 2021-10-12 | 2023-04-20 | Modernatx, Inc. | Compositions comprising modified rna encoding vegf-a and methods of use |
| WO2023084013A1 (en) * | 2021-11-12 | 2023-05-19 | Modernatx, Inc. | Compositions comprising modified rna encoding vegf-a and methods of use |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004035227A1 (de) * | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| WO2006086798A2 (en) | 2005-02-08 | 2006-08-17 | Board Of Regents, The University Of Texas System | Compositions and methods involving mda-7 for the treatment of cancer |
| WO2010065601A1 (en) | 2008-12-03 | 2010-06-10 | Amorcyte, Inc. | Infarct area perfusion-improving compositions and methods of vascular injury repair |
| CA2746003C (en) | 2008-12-04 | 2020-03-31 | Opko Curna, Llc | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
| WO2011069529A1 (en) * | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| AU2011358150B2 (en) | 2010-12-16 | 2016-11-03 | Sprna Gmbh | Pharmaceutical composition consisting of RNA having alkali metal as counter ion and formulated with dications |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| US10086043B2 (en) | 2011-04-03 | 2018-10-02 | The General Hospital Corporation | Efficient protein expression in vivo using modified RNA (MOD-RNA) |
| SI2791160T1 (sl) | 2011-12-16 | 2022-07-29 | Modernatx, Inc. | Sestave modificirane MRNA |
| RU2014129863A (ru) | 2011-12-21 | 2016-02-10 | Модерна Терапьютикс, Инк. | Способы повышения жизнеспособности или увеличения продолжительности жизни органа или экспланта органа |
| AU2013243952A1 (en) * | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| US20140275229A1 (en) * | 2012-04-02 | 2014-09-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1 |
| US9663564B2 (en) | 2013-03-15 | 2017-05-30 | The Regents Of The University Of California | Vectors and methods to treat ischemia |
| EP2971010B1 (en) * | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| SG10201801428RA (en) | 2013-08-21 | 2018-03-28 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| JP6786392B2 (ja) * | 2014-01-15 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ＦｃＲｎ結合特性が改変され、プロテインＡ結合特性が保持されているＦｃ領域変異体 |
| WO2016118725A1 (en) | 2015-01-23 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| CA2998810A1 (en) | 2015-09-17 | 2017-03-23 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| CN116606861A (zh) | 2016-06-07 | 2023-08-18 | 摩登纳特斯有限公司 | 编码vegf-a多肽的经修饰的rna、配制品和关于它们的用途 |
| US11542490B2 (en) | 2016-12-08 | 2023-01-03 | CureVac SE | RNAs for wound healing |
| MX389934B (es) | 2016-12-09 | 2025-03-20 | Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A De C V | Composición coadyuvante de un factor de crecimiento y un neuropéptido para acelerar la cicatrización de heridas y la repitelización de órganos. |
| WO2019089818A1 (en) | 2017-10-31 | 2019-05-09 | Modernatx, Inc. | Lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide |
| EP3965797A1 (en) | 2019-05-08 | 2022-03-16 | AstraZeneca AB | Compositions for skin and wounds and methods of use thereof |
-
2017
- 2017-06-06 CN CN202310693718.2A patent/CN116606861A/zh active Pending
- 2017-06-06 AU AU2017277277A patent/AU2017277277B2/en not_active Ceased
- 2017-06-06 PT PT177348851T patent/PT3464338T/pt unknown
- 2017-06-06 DK DK17734885.1T patent/DK3464338T3/da active
- 2017-06-06 SM SM20210586T patent/SMT202100586T1/it unknown
- 2017-06-06 CA CA3026500A patent/CA3026500A1/en active Pending
- 2017-06-06 US US16/305,224 patent/US11866475B2/en active Active
- 2017-06-06 JP JP2018564389A patent/JP6859369B2/ja active Active
- 2017-06-06 HU HUE17734885A patent/HUE056055T2/hu unknown
- 2017-06-06 HR HRP20211569TT patent/HRP20211569T1/hr unknown
- 2017-06-06 EP EP17734885.1A patent/EP3464338B1/en active Active
- 2017-06-06 MA MA45172A patent/MA45172B1/fr unknown
- 2017-06-06 KR KR1020197000227A patent/KR102376245B1/ko not_active Expired - Fee Related
- 2017-06-06 CN CN201780048447.8A patent/CN109790207B/zh active Active
- 2017-06-06 SG SG10202012175YA patent/SG10202012175YA/en unknown
- 2017-06-06 RS RS20211280A patent/RS62556B1/sr unknown
- 2017-06-06 KR KR1020227008509A patent/KR102494499B1/ko active Active
- 2017-06-06 MX MX2018015110A patent/MX2018015110A/es unknown
- 2017-06-06 RU RU2018147229A patent/RU2756313C2/ru active
- 2017-06-06 WO PCT/US2017/036188 patent/WO2017214175A1/en not_active Ceased
- 2017-06-06 EP EP21186195.0A patent/EP3971204A1/en not_active Withdrawn
- 2017-06-06 ES ES17734885T patent/ES2895421T3/es active Active
- 2017-06-06 SG SG11201810816QA patent/SG11201810816QA/en unknown
- 2017-06-06 SI SI201730935T patent/SI3464338T1/sl unknown
- 2017-06-06 PL PL17734885T patent/PL3464338T3/pl unknown
- 2017-06-06 KR KR1020237003204A patent/KR102552543B1/ko active Active
- 2017-06-06 LT LTEPPCT/US2017/036188T patent/LT3464338T/lt unknown
- 2017-06-06 KR KR1020237022229A patent/KR20230107891A/ko not_active Ceased
- 2017-06-07 TW TW106118838A patent/TWI752036B/zh not_active IP Right Cessation
- 2017-06-07 TW TW110145699A patent/TWI818375B/zh not_active IP Right Cessation
-
2018
- 2018-11-29 IL IL263370A patent/IL263370A/en unknown
-
2021
- 2021-03-24 JP JP2021049671A patent/JP7167226B2/ja active Active
- 2021-10-14 CY CY20211100889T patent/CY1124667T1/el unknown
-
2022
- 2022-10-26 JP JP2022171389A patent/JP2023011733A/ja active Pending
-
2023
- 2023-07-28 AU AU2023208200A patent/AU2023208200A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109790207B (zh) | 编码vegf-a多肽的经修饰的rna、配制品和关于它们的用途 | |
| Carlsson et al. | Biocompatible, purified VEGF-A mRNA improves cardiac function after intracardiac injection 1 week post-myocardial infarction in swine | |
| Hsieh et al. | Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers | |
| Wang et al. | Ghrelin ameliorates impaired angiogenesis of ischemic myocardium through GHSR1a-mediated AMPK/eNOS signal pathway in diabetic rats | |
| Funatsu et al. | Therapeutic angiogenesis in the ischemic canine heart induced by myocardial injection of naked complementary DNA plasmid encoding hepatocyte growth factor | |
| Liu et al. | Placental growth factor increases regional myocardial blood flow and contractile function in chronic myocardial ischemia | |
| EA009390B1 (ru) | Плазмида, кодирующая фактор роста фибробластов, для лечения ангиогенных дефектов, ассоциированных с гиперхолестеринемией или диабетом | |
| Schwarz et al. | Monocyte chemoattractant protein 1-induced monocyte infiltration produces angiogenesis but not arteriogenesis in chronically infarcted myocardium | |
| HK40070904A (en) | Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto | |
| Wang et al. | Recombinant human hepatocyte growth factor transfection alleviates hyperkinetic pulmonary artery hypertension in rabbit models | |
| HK40007104B (en) | Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto | |
| Choi et al. | Dickkopf 2–Expressing Adenovirus Increases the Survival of Random-Pattern Flaps and Promotes Vasculogenesis in a Rat Model | |
| US20230220026A1 (en) | Nucleic acid carrier for producing the single-chain vegf fusion protein with high physiological stability and dimeric efficiency, preparation method thereof, and use thereof | |
| Mitsos et al. | Intramyocardial thrombin promotes angiogenesis and improves cardiac function in an experimental rabbit model of acute myocardial infarction | |
| WO2006062087A1 (ja) | 心筋障害又は心不全の治療もしくは予防組成物 | |
| Wang et al. | Cavitation by Ultrasound | |
| CN116440163A (zh) | 一种用于哺乳动物骨骼和/或肌肉抗衰的生物制品及其制备方法和应用 | |
| CN1681525A (zh) | 一种抑制血管渗漏和组织水肿的方法 | |
| Denby | Cardiac Regeneration Following Myocardial Infarction in a Rat Model of Diabetic Cardiomyopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |